Citations

Clear

2966 citation(s) found for "Go, Ronald S".

P3–093: FDG‐PET and PiB‐PET imaging in asymptomatic at‐risk carriers of a novel octapeptide repeat insertion in PRNP
Lowe, Val J. , Przybelski, Scott A. , Weigand, Stephen D. , Spychalla, Anthony J., Jones, David, Kumar, Neeraj , Rademakers, Rosa , Petersen, Ronald, Parisi, Joseph, Boeve, Bradley F. , Kantarci, Kejal , Vemuri, Prashanthi , Jones, David, McDade, Eric , Baker, Matthew , Knopman, David S. , Petersen, Ronald, Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2013.05.1163 Get It

P3–125: Rates of atrophy differ across pathologically defined subtypes of Alzheimer's disease: A longitudinal MRI study
Whitwell, Jennifer , Gunter, Jeffrey L. , Spychalla, Anthony J., Petersen, Ronald, Josephs, Keith A. , Dickson, Dennis W. , Murray, Melissa E. , Senjem, Matthew L. , Petersen, Ronald, Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2013.05.1196 Get It

P2–200: Self‐ versus informant‐based cognitive complaints: Relation of E‐Cog scores to imaging, biomarkers and clinical Status in ADNI‐2
Petersen, Ronald C. , Aisen, Paul , Koeppe, Robert, Jagust, William, Farias, Sarah Tomaszewski , Mungas, Dan , Trojanowski, John Q., Shaw, Leslie, Weiner, Michael W. , Risacher, Shannon L. , Jack, Clifford R. , Trojanowski, John Q., Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_10 | Pages: No page available

10.1016/j.jalz.2013.05.845 Get It

IC‐P‐073: Aberrant tau and amyloid pathology underlies 1H MR spectroscopic alterations in Alzheimer's disease and Lewy body disease
Murray, Melissa E. , Przybelski, Scott A. , Lesnick, Timothy G. , Liesinger, Amanda M., Spychalla, Anthony J., Gunter, Jeffrey L. , Parisi, Joseph, Petersen, Ronald, Boeve, Bradley F. , Knopman, David S. , Petersen, Ronald, Dickson, Dennis W. , Kantarci, Kejal , Murray, Melissa E

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2013.05.070 Get It

IC‐P‐060: MRS differentiates MCI patients who progress to dementia with Lewy bodies and Alzheimer's disease
Zhang, Bing , Maroney‐Smith, Mandie, Petersen, Ronald C. , Ferman, Tanis J. , Boeve, Bradley F. , Smith, Glenn E. , Knopman, David S. , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2013.05.056 Get It

IC‐P‐105: Self‐reported versus informant‐based cognitive complaints: Relation of E‐Cog scores to imaging biomarkers and clinical status in ADNI‐2
Petersen, Ronald C. , Aisen, Paul , Jagust, William J. , Farias, Sarah Tomaszewski , Mungas, Dan , Trojanowski, John Q., Shaw, Leslie M. , Weiner, Michael W. , Risacher, Shannon L. , Jack, Clifford R. , Koeppe, Robert A. , Trojanowski, John Q., Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2013.05.102 Get It

Is α-synuclein rising to the surface as a diagnostic biomarker for Parkinson disease?
Cheshire, William P. , Pfeiffer, Ronald F. , Cheshire, William P

Mayo Clinic

Neurology | October 3, 2013 | Volume: 81 | Issue: 18 | Pages: 1568-1569

10.1212/wnl.0b013e3182a9f5ab | PMID 24089391 Get It

Studies of Retinopathy: Methodology for Assessment and Classification with Fundus Photographs
Davis, Matthew D. , Hubbard, Larry D., Trautman, James, Group, The Kroc Collaborative Study, Klein, Ronald , Group, The Kroc Collaborative Study

Mayo Clinic

Diabetes | September 19, 2013 | Volume: 34 | Issue: Supplement_3 | Pages: 42-49

10.2337/diab.34.3.s42 | PMID 4018420 Get It

A major goal of the study was to assess the methodologies available for the quantification of retinal lesions suitable for application in trials of metabolic management. We describe the methods used for grading stereoscopic color fundus photographs. Overall retinopathy severity level for each eye ranging from normal (level 10) to high-risk category (level 70) was assigned on the basis of gradings of individual lesions. Change in retinopathy severity level over the 8-mo period was detected in 3–62% of patients, depending on the method used and the definition of change. Lesions responsible for change in level were mainly retinal infarcts (soft exudates) and intraretinal microvascular abnormalities.
Pediatric melanoma: Analysis of an international registry
Averbook, Bruce J., Delman, Keith A. , Gow, Kenneth W. , Sondak, Vernon K. , Messina, Jane L. , Pittelkow, Mark R. , Ecker, Phillip M., Testori, Alessandro , Curiel‐Lewandrowski, Clara , Jukic, D.M., Lee, Sandra J. , Zager, Jonathan S. , Sabel, Michael S. , Markovic, Svetomir N. , Swetter, Susan M. , Leachman, Sancy A. , Go, Ronald S. , Kirkwood, John M.

Mayo Clinic

Cancer | September 11, 2013 | Volume: 119 | Issue: 22 | Pages: 4012-4019

10.1002/cncr.28289 | PMID 24022819 Get It

BACKGROUNDThe management of pediatric melanoma (PM) has largely been extrapolated from adult data. However, the behavior of PM appears to differ from its adult counterparts. Therefore, an international PM registry was created and analyzed.METHODSTwelve institutions contributed deidentified clinicopathologic and outcome data for patients diagnosed with PM from 1953 through 2008.RESULTSOverall survival (OS) data were reported for 365 patients with invasive PM who had adequate follow‐up data. The mean age of the patients was 16 years (range 1 year‐21 years). The 10‐year OS rate, 80.6%, tended to vary by patient age: 100% for those aged birth to 10 years, 69.7% for those aged > 10 years to 15 years, and 79.5% for those aged > 15 years to 20 years (P = .147). Patients with melanomas measuring ≤ 1 mm had a favorable prognosis (10‐year OS rate of 97%), whereas survival was lower but similar for patients with melanomas measuring > 1 mm to 2 mm, > 2 mm to 4 mm, and > 4 mm (70%, 78%, and 80%, respectively; P = .0077). Ulceration and lymph node metastasis were found to be correlated with worse survival (P = .022 and P = .017, respectively). The 10‐year OS rate was 94.1% for patients with American Joint Committee on Cancer stage I disease, 79.6% for those with stage II disease, and 77.1% for patients with stage III disease (P < .001).CONCLUSIONSTumor thickness, ulceration, lymph node status, and stage were found to be significant predictors of survival in patients with PM, similar to adult melanoma. There is a trend toward increased survival in children aged ≤ 10 years versus adolescents aged > 10 years. Further analyses are needed to probe for potential biological and behavioral differences in pediatric versus adult melanoma. Cancer 2013;119:4012–4019. © 2013 American Cancer Society.